Explore

Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with Dual-Payload ADCs
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Treatment with ADC Technology
Trendline Trendline
CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology

CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology

CrossBridge Bio Acquired by Eli Lilly to Advance Cancer Treatment Technology
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio, Reinforcing Linden Lake Labs' ADC Platform

Eli Lilly Acquires CrossBridge Bio, Reinforcing Linden Lake Labs' ADC Platform

Eli Lilly Acquires CrossBridge Bio, Reinforcing Linden Lake Labs' ADC Platform
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development

Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development

Kivu Bioscience Names Mohit Trikha as New CEO to Lead ADC Development
Trendline Trendline
Seragon Biosciences Reports Longevity Drug SRN-901 Extends Lifespan in Mice

Seragon Biosciences Reports Longevity Drug SRN-901 Extends Lifespan in Mice

Seragon Biosciences Reports Longevity Drug SRN-901 Extends Lifespan in Mice
Trendline Trendline
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Advance Protein Degradation Platform

Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Advance Protein Degradation Platform

Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Advance Protein Degradation Platform
Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Stanford University Hosts Premier Drug Discovery Symposium to Advance Future of Drug Development

Stanford University Hosts Premier Drug Discovery Symposium to Advance Future of Drug Development

Stanford University Hosts Premier Drug Discovery Symposium to Advance Future of Drug Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal

Eli Lilly Acquires CrossBridge Bio to Enhance Cancer Care with $300M Deal